Saturday Rounds: Week of August 16–22, 2026

Biotech had an approval week. Ultragenyx’s first-ever gene therapy for glycogen storage disease type Ia, Regeneron’s second-ever disease-modifying therapy for fibrodysplasia ossificans progressiva, and Amylyx’s blowout Phase 3 win in post-bariatric hypoglycemia landed within 48 hours of each other and sent XBI up nearly 6%…